VIR Relative Valuation
VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VIR is overvalued; if below, it's undervalued.
Historical Valuation
Vir Biotechnology Inc (VIR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 66.52 is considered Overvalued compared with the five-year average of -7.24. The fair price of Vir Biotechnology Inc (VIR) is between 2.51 to 4.73 according to relative valuation methord. Compared to the current price of 5.41 USD , Vir Biotechnology Inc is Overvalued By 14.44%.
Relative Value
Fair Zone
2.51-4.73
Current Price：5.41
14.44%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.72
P/B
Median3y
1.11
Median5y
3.14
-57.62
FCF Yield
Median3y
-18.28
Median5y
-10.63
Competitors Valuation Multiple
The average P/S ratio for VIR's competitors is 112.92, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR) exhibits a P/S ratio of 66.52, which is -41.09% above the industry average. Given its robust revenue growth of -94.62%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Vir Biotechnology Inc (VIR) currently overvalued or undervalued?
What is Vir Biotechnology Inc (VIR) fair value?
How does VIR's valuation metrics compare to the industry average?
What is the current P/B ratio for Vir Biotechnology Inc (VIR) as of Jul 19 2025?
What is the current FCF Yield for Vir Biotechnology Inc (VIR) as of Jul 19 2025?
What is the current Forward P/E ratio for Vir Biotechnology Inc (VIR) as of Jul 19 2025?